Altimmune (ALT)
Market Price (5/13/2026): $3.09 | Market Cap: $327.0 MilSector: Health Care | Industry: Biotechnology
Altimmune (ALT)
Market Price (5/13/2026): $3.09Market Cap: $327.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -73% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 105% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -53% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -117% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -94 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -230461% Expensive valuation multiplesP/SPrice/Sales ratio is 7,949x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 39210% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -164720%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -164722% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 33% Key risksALT key risks include [1] the uncertain clinical and regulatory outcome for its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -73% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 105% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -53% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -117% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -94 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -230461% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 7,949x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 39210% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -164720%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -164722% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 33% |
| Key risksALT key risks include [1] the uncertain clinical and regulatory outcome for its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Fourth Quarter 2025 Earnings Miss and Elevated R&D Costs.
Altimmune reported a GAAP loss per share of ($0.27) for the fourth quarter of 2025 on March 5, 2026, missing analysts' consensus estimates of ($0.25) by $0.02. This larger-than-expected loss was partly attributed to higher-than-anticipated Research and Development (R&D) expenses, which reached $18.4 million compared to a consensus of $17.4 million, leading to an approximate 7% decline in the stock price following the announcement.
2. Public Offering and Share Dilution.
In April 2026, Altimmune completed a $225 million oversubscribed public offering of securities, with shares and warrants sold at approximately $3.00. While this offering secured funding for the planned Phase 3 MASH program and removed near-term financing risk, such public offerings typically lead to dilution of existing shareholder value, which can exert downward pressure on the stock price.
Show more
Stock Movement Drivers
Fundamental Drivers
The -45.0% change in ALT stock from 1/31/2026 to 5/12/2026 was primarily driven by a -68.2% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.60 | 3.08 | -45.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 105.0% |
| P/S Multiple | 25,037.0 | 7,949.5 | -68.2% |
| Shares Outstanding (Mil) | 89 | 106 | -15.5% |
| Cumulative Contribution | -45.0% |
Market Drivers
1/31/2026 to 5/12/2026| Return | Correlation | |
|---|---|---|
| ALT | -45.0% | |
| Market (SPY) | 3.6% | 43.4% |
| Sector (XLV) | -5.4% | 29.4% |
Fundamental Drivers
The -24.0% change in ALT stock from 10/31/2025 to 5/12/2026 was primarily driven by a -51.8% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.05 | 3.08 | -24.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 105.0% |
| P/S Multiple | 16,499.2 | 7,949.5 | -51.8% |
| Shares Outstanding (Mil) | 81 | 106 | -23.0% |
| Cumulative Contribution | -24.0% |
Market Drivers
10/31/2025 to 5/12/2026| Return | Correlation | |
|---|---|---|
| ALT | -24.0% | |
| Market (SPY) | 5.5% | 25.7% |
| Sector (XLV) | 2.0% | 20.7% |
Fundamental Drivers
The -41.3% change in ALT stock from 4/30/2025 to 5/12/2026 was primarily driven by a -57.5% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.25 | 3.08 | -41.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 105.0% |
| P/S Multiple | 18,698.4 | 7,949.5 | -57.5% |
| Shares Outstanding (Mil) | 71 | 106 | -32.7% |
| Cumulative Contribution | -41.3% |
Market Drivers
4/30/2025 to 5/12/2026| Return | Correlation | |
|---|---|---|
| ALT | -41.3% | |
| Market (SPY) | 30.4% | 20.2% |
| Sector (XLV) | 5.7% | 20.2% |
Fundamental Drivers
The -39.0% change in ALT stock from 4/30/2023 to 5/12/2026 was primarily driven by a -313.8% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5122026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.05 | 3.08 | -39.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | -0 | 0 | -160.3% |
| P/S Multiple | -3,717.7 | 7,949.5 | -313.8% |
| Shares Outstanding (Mil) | 50 | 106 | -52.7% |
| Cumulative Contribution | -39.0% |
Market Drivers
4/30/2023 to 5/12/2026| Return | Correlation | |
|---|---|---|
| ALT | -39.0% | |
| Market (SPY) | 78.7% | 26.2% |
| Sector (XLV) | 14.8% | 23.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALT Return | -19% | 80% | -32% | -36% | -50% | -14% | -73% |
| Peers Return | 18% | 78% | 22% | 35% | 29% | -5% | 326% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| ALT Win Rate | 33% | 42% | 33% | 42% | 50% | 40% | |
| Peers Win Rate | 50% | 53% | 42% | 50% | 47% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ALT Max Drawdown | -25% | -57% | -87% | -51% | -53% | -28% | |
| Peers Max Drawdown | -15% | -26% | -30% | -10% | -20% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VKTX, MDGL, LLY, AMGN, PFE. See ALT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/12/2026 (YTD)
How Low Can It Go
| Event | ALT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.9% | -18.8% |
| % Gain to Breakeven | 84.7% | 23.1% |
| Time to Breakeven | 65 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -26.5% | -7.8% |
| % Gain to Breakeven | 36.0% | 8.5% |
| Time to Breakeven | 12 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.7% | -9.5% |
| % Gain to Breakeven | 40.2% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -75.1% | -6.7% |
| % Gain to Breakeven | 301.5% | 7.1% |
| Time to Breakeven | 235 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -58.3% | -24.5% |
| % Gain to Breakeven | 139.8% | 32.4% |
| Time to Breakeven | 43 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -63.8% | -19.2% |
| % Gain to Breakeven | 176.2% | 23.7% |
| Time to Breakeven | 512 days | 105 days |
In The Past
Altimmune's stock fell -45.9% during the 2025 US Tariff Shock. Such a loss loss requires a 84.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ALT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.9% | -18.8% |
| % Gain to Breakeven | 84.7% | 23.1% |
| Time to Breakeven | 65 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -26.5% | -7.8% |
| % Gain to Breakeven | 36.0% | 8.5% |
| Time to Breakeven | 12 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.7% | -9.5% |
| % Gain to Breakeven | 40.2% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -75.1% | -6.7% |
| % Gain to Breakeven | 301.5% | 7.1% |
| Time to Breakeven | 235 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -58.3% | -24.5% |
| % Gain to Breakeven | 139.8% | 32.4% |
| Time to Breakeven | 43 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -63.8% | -19.2% |
| % Gain to Breakeven | 176.2% | 23.7% |
| Time to Breakeven | 512 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -80.8% | -3.7% |
| % Gain to Breakeven | 420.0% | 3.9% |
| Time to Breakeven | 1 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -43.2% | -6.8% |
| % Gain to Breakeven | 76.2% | 7.3% |
| Time to Breakeven | 200 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -46.2% | -17.9% |
| % Gain to Breakeven | 85.9% | 21.8% |
| Time to Breakeven | 1816 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -78.2% | -53.4% |
| % Gain to Breakeven | 358.8% | 114.4% |
| Time to Breakeven | 299 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -44.9% | -8.6% |
| % Gain to Breakeven | 81.4% | 9.5% |
| Time to Breakeven | 3435 days | 47 days |
In The Past
Altimmune's stock fell -45.9% during the 2025 US Tariff Shock. Such a loss loss requires a 84.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Altimmune (ALT)
AI Analysis | Feedback
Here are 1-2 brief analogies for Altimmune (ALT):
- Altimmune is like Eli Lilly or Novo Nordisk for next-generation obesity and liver disease treatments.
- Altimmune is an early-stage biotech aiming to be the next Eli Lilly or Novo Nordisk in the metabolic disease space.
AI Analysis | Feedback
- Pemvidutide (ALT-801): A GLP-1/glucagon dual receptor agonist in clinical trials for treating obesity and non-alcoholic steatohepatitis.
- HepTcell: An immunotherapeutic product candidate in clinical trials for patients with chronic hepatitis B virus infection.
AI Analysis | Feedback
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. As a clinical-stage company, its primary activities involve research and development, including conducting clinical trials for its product candidates like pemvidutide and HepTcell.
At this stage, Altimmune does not have commercialized products on the market, and therefore, it does not have major customers in the traditional sense, whether they be other companies or individuals. The company's focus is on bringing its drug candidates through the development and regulatory approval process.
AI Analysis | Feedback
null
AI Analysis | Feedback
Jerome Durso President, Chief Executive Officer and Chairman Of The Board
Jerome Durso was appointed President and Chief Executive Officer of Altimmune, Inc. effective January 1, 2026, while also retaining his role as Chairman of the Board. He has over 30 years of leadership experience in the life sciences industry.
Greg Weaver, MBA Chief Financial Officer
Greg Weaver joined Altimmune as Chief Financial Officer in November 2024. He brings over 25 years of finance experience across publicly-traded and privately-held life sciences companies. Prior to Altimmune, he was CFO of Cognito Therapeutics, and before that, CFO at atai Life Sciences (Nasdaq: ATAI), where he led a $225 million Initial Public Offering in 2021. Earlier in his career, he served as CFO at publicly-traded biotech companies including Sirna Therapeutics, which was acquired by Merck, and ILEX Oncology, which was acquired by Genzyme.
Linda M. Richardson, BA Chief Commercial Officer
Linda M. Richardson was appointed Chief Commercial Officer of Altimmune, Inc. effective September 16, 2025.
Christophe Arbet-Engels, M.D., Ph.D. Chief Medical Officer
Christophe Arbet-Engels was appointed Chief Medical Officer of Altimmune, Inc. effective October 1, 2025.
M. Scot Roberts, Ph.D. Chief Scientific Officer
Dr. Scot Roberts has served as the Chief Scientific Officer for Altimmune since December 2012. He has over two decades of experience managing scientific operations, leading research and drug development efforts for both small molecules and biologics, with a focus on viral vectors and antiviral therapies. Before joining Altimmune, Dr. Roberts was the Chief Scientific Officer for ImQuest BioSciences, Inc., where he was responsible for scientific operations and business development in cancer and antivirals. He also held several leadership positions at Wellstat Biologics Corporation, including Director of Research and Development.
AI Analysis | Feedback
Here are the key risks to Altimmune's business:
- Clinical Development and Regulatory Risk for Pemvidutide: Altimmune's core business relies heavily on the successful clinical development, regulatory approval, and commercialization of its lead product candidate, pemvidutide. While pemvidutide has shown promising results in clinical trials and received FDA Breakthrough Therapy designation for Metabolic Dysfunction-Associated Steatohepatitis (MASH), there are inherent uncertainties. The Phase 2b IMPACT trial for MASH met the primary endpoint of MASH resolution but did not achieve fibrosis improvement at 24 weeks, necessitating longer duration trials. Additionally, earlier data for obesity raised safety concerns regarding gastrointestinal adverse events leading to discontinuations at higher doses. The company's plan to introduce dose titration in the upcoming Phase 3 MASH program, a change from its prior "no titration" strategy, could impact pemvidutide's tolerability and its competitive advantage. The high failure rate, potential for delays, and significant costs associated with clinical trials pose a continuous and substantial risk to Altimmune. The company's past decision to halt development of its HepTcell program due to insufficient efficacy in Phase 2 trials underscores the challenges and risks of drug development.
- Intense Competition and Market Positioning for Pemvidutide: The markets for obesity and MASH treatments are highly competitive and rapidly expanding. Pemvidutide, a GLP-1/glucagon dual receptor agonist, faces significant competition from established pharmaceutical companies and other developing GLP-1-based therapies. The increasing commoditization of GLP-1 therapies could erode pemvidutide's potential differentiation and pricing power. Altimmune's ability to secure strategic partnerships for the costly commercialization of pemvidutide, particularly for its planned Phase 3 MASH program, remains a concern, as the absence of such collaborations could hinder its market entry and success.
- Financial Risk and Need for Additional Funding: As a clinical-stage biopharmaceutical company with no commercial products, Altimmune consistently reports financial losses and rising expenses. Although the company maintains a strong cash position that is projected to fund operations into 2028, the advancement of pemvidutide into late-stage (Phase 3) clinical trials, especially for MASH, will require substantial capital. Analysts do not anticipate profitability for Altimmune in the near future, and a projected funding gap could necessitate future equity dilution or increased debt if strategic partnerships or other funding sources are not secured.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Markets for Altimmune's Main Products:
Pemvidutide (Obesity)
- Global: The global obesity treatment market was valued at approximately USD 15.74 billion in 2024 and is projected to reach around USD 98.26 billion by 2034.
- U.S.: The U.S. obesity treatment market generated revenue of USD 11,194.0 million in 2024 and is expected to reach USD 48,498.2 million by 2030.
Pemvidutide (Non-alcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis - NASH/MASH)
- Global: The global Non-Alcoholic Steatohepatitis Treatment Market was valued at USD 7.70 billion in 2024 and is projected to reach USD 55.52 billion by 2032.
- U.S.: The U.S. NASH treatment market accounted for approximately USD 4.56 billion in 2024 and is forecast to rise to USD 32.55 billion by 2032.
HepTcell (Chronic Hepatitis B Virus)
- null
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Altimmune (ALT) over the next 2-3 years:
- Advancement and Potential Commercialization of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Altimmune plans to initiate a global Phase 3 MASH trial for pemvidutide in 2026, building on positive 24-week Phase 2b data that demonstrated significant MASH resolution without worsening of fibrosis, along with meaningful reductions in fibrosis and liver fat. The 48-week data from the IMPACT Phase 2b MASH trial is anticipated in the fourth quarter of 2025. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Successful progression through Phase 3 and potential accelerated approval could pave the way for market entry or lucrative partnerships, driving significant revenue.
- Advancement and Potential Commercialization of Pemvidutide in Obesity: Following successful End-of-Phase 2 meetings with the FDA in late 2024 to clarify the Phase 3 design, Altimmune is preparing for a Phase 3 obesity registrational program for pemvidutide. The program will include four pivotal trials focusing on weight loss and evaluating effects on comorbidities such as elevated serum lipids and liver fat. Pemvidutide's differentiated profile, including significant weight loss with class-leading preservation of lean mass (74.5% fat loss, 25.5% lean mass loss), positions it uniquely in the competitive obesity market. Future positive clinical trial outcomes could lead to commercial partnerships or market penetration, tapping into a global obesity market projected to reach $31.1 billion by 2031.
- Expansion of Pemvidutide into New Indications: Altimmune is exploring additional indications for pemvidutide, with plans to submit Investigational New Drug (IND) applications for up to three new areas starting in Q4 2024. Specifically, Phase 2 trials for pemvidutide in Alcohol Use Disorder (RECLAIM) and Alcohol-Associated Liver Disease (RESTORE) were initiated in May 2025 and July 2025, respectively. Topline results from the Phase 2 RECLAIM trial for AUD are anticipated in Q3 2026. Positive results in these areas could open up new significant markets for pemvidutide, diversifying future revenue streams beyond obesity and MASH.
- Strategic Partnerships and Licensing Deals for Pemvidutide: As a clinical-stage biopharmaceutical company with no current commercial revenue, Altimmune's future revenue growth is heavily reliant on securing strategic partnerships or licensing agreements for pemvidutide. Successful data readouts from its ongoing and upcoming Phase 2 and Phase 3 trials in MASH, obesity, and other indications are critical catalysts that could attract large pharmaceutical partners, leading to upfront payments, milestone payments, and royalties, thereby driving significant revenue growth.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Issuance
- In January 2026, Altimmune closed a registered direct offering of common stock and pre-funded warrants, generating gross proceeds of approximately $75 million.
- The company raised an additional $8.0 million through its At-the-Market (ATM) facility in January 2026.
- During 2025, Altimmune recorded net equity capital raised totaling approximately $174 million.
Inbound Investments
- Altimmune completed a $75 million registered direct offering in January 2026 with Alyeska Investment Group, a new fundamental institutional investor.
- In 2025, the company received $35 million in funding from the Hercules tranche loan facility.
Capital Expenditures
- Capital expenditures for the year ended December 31, 2025, were minimal, approximately $11K.
- The company's capital expenditures are not a primary focus as it does not operate a large manufacturing infrastructure.
- Future capital expenditures are expected to remain minimal, with the main spending concentrated on research and development for clinical trials.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ALT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 183.81 |
| Mkt Cap | 81.0 |
| Rev LTM | 19,176 |
| Op Inc LTM | 5,237 |
| FCF LTM | 4,265 |
| FCF 3Y Avg | 830 |
| CFO LTM | 5,344 |
| CFO 3Y Avg | 5,137 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 47.4% |
| Rev Chg 3Y Avg | 25.2% |
| Rev Chg Q | 55.5% |
| QoQ Delta Rev Chg LTM | 10.8% |
| Op Inc Chg LTM | 17.3% |
| Op Inc Chg 3Y Avg | 2.7% |
| Op Mgn LTM | 24.5% |
| Op Mgn 3Y Avg | 21.0% |
| QoQ Delta Op Mgn LTM | 3.6% |
| CFO/Rev LTM | 18.9% |
| CFO/Rev 3Y Avg | 19.0% |
| FCF/Rev LTM | 14.4% |
| FCF/Rev 3Y Avg | 7.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 81.0 |
| P/S | 12.3 |
| P/Op Inc | 3.0 |
| P/EBIT | 5.1 |
| P/E | 8.0 |
| P/CFO | 3.7 |
| Total Yield | 0.7% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | -2.1% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.3% |
| 3M Rtn | -4.0% |
| 6M Rtn | -2.7% |
| 12M Rtn | 23.1% |
| 3Y Rtn | 48.8% |
| 1M Excs Rtn | -11.3% |
| 3M Excs Rtn | -10.6% |
| 6M Excs Rtn | -4.6% |
| 12M Excs Rtn | -3.4% |
| 3Y Excs Rtn | -32.3% |
Comparison Analyses
Price Behavior
| Market Price | $3.08 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 10/06/2005 | |
| Distance from 52W High | -60.1% | |
| 50 Days | 200 Days | |
| DMA Price | $3.30 | $3.99 |
| DMA Trend | down | down |
| Distance from DMA | -6.7% | -22.9% |
| 3M | 1YR | |
| Volatility | 73.4% | 92.5% |
| Downside Capture | 2.08 | 1.09 |
| Upside Capture | 153.33 | 75.24 |
| Correlation (SPY) | 39.1% | 17.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.53 | 2.45 | 1.87 | 1.59 | 1.51 | 1.60 |
| Up Beta | 0.57 | 1.14 | 1.19 | 1.22 | 0.86 | 1.59 |
| Down Beta | 7.85 | -0.44 | 0.64 | -0.12 | 0.80 | 1.45 |
| Up Capture | 170% | 221% | 113% | 203% | 132% | 265% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 16 | 20 | 49 | 106 | 335 |
| Down Capture | 1704% | 427% | 307% | 212% | 178% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 25 | 42 | 72 | 138 | 404 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALT | |
|---|---|---|---|---|
| ALT | -39.2% | 92.3% | -0.03 | - |
| Sector ETF (XLV) | 11.9% | 15.5% | 0.53 | 18.0% |
| Equity (SPY) | 28.3% | 12.5% | 1.80 | 17.2% |
| Gold (GLD) | 41.3% | 26.9% | 1.26 | 5.0% |
| Commodities (DBC) | 47.5% | 18.0% | 2.10 | -8.9% |
| Real Estate (VNQ) | 12.8% | 13.5% | 0.65 | 16.1% |
| Bitcoin (BTCUSD) | -21.0% | 41.7% | -0.46 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALT | |
|---|---|---|---|---|
| ALT | -23.9% | 94.6% | 0.18 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 19.8% |
| Equity (SPY) | 12.9% | 17.1% | 0.59 | 23.8% |
| Gold (GLD) | 21.0% | 17.9% | 0.95 | 3.9% |
| Commodities (DBC) | 13.4% | 19.1% | 0.57 | 0.0% |
| Real Estate (VNQ) | 3.9% | 18.8% | 0.11 | 23.7% |
| Bitcoin (BTCUSD) | 7.2% | 55.9% | 0.34 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALT | |
|---|---|---|---|---|
| ALT | -27.5% | 384.6% | 0.38 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 2.4% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 3.9% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 1.7% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 2.8% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 2.9% |
| Bitcoin (BTCUSD) | 68.2% | 66.8% | 1.07 | 2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | -17.9% | -11.0% | -21.8% |
| 11/6/2025 | 5.1% | 12.8% | 49.6% |
| 8/12/2025 | 7.1% | 5.3% | 8.6% |
| 5/13/2025 | -4.2% | -8.5% | 8.8% |
| 2/27/2025 | 8.1% | -3.7% | -6.2% |
| 11/12/2024 | 29.1% | -2.7% | 18.9% |
| 8/8/2024 | 15.1% | 12.4% | 12.7% |
| 3/27/2024 | 2.8% | 7.4% | -16.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 11 | 11 |
| # Negative | 4 | 10 | 10 |
| Median Positive | 7.0% | 7.4% | 18.9% |
| Median Negative | -10.2% | -7.7% | -16.9% |
| Max Positive | 29.1% | 33.7% | 157.7% |
| Max Negative | -17.9% | -26.6% | -62.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/06/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gill, John | Direct | Buy | 4062026 | 3.41 | 9,200 | 31,350 | 73,945 | Form | |
| 2 | Weaver, Gregory L | Chief Financial Officer | Direct | Buy | 4012026 | 3.15 | 10,000 | 31,499 | 119,942 | Form |
| 3 | Durso, Jerome Benedict | President and CEO | Direct | Buy | 4012026 | 3.14 | 15,000 | 47,100 | 149,150 | Form |
| 4 | Durso, Jerome Benedict | President and CEO | Direct | Buy | 3092026 | 3.54 | 20,000 | 70,790 | 115,034 | Form |
| 5 | Weaver, Gregory L | Chief Financial Officer | Direct | Buy | 3092026 | 3.54 | 5,000 | 17,700 | 99,396 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.